MedPath

Iron supplementation in early infancy

Phase 3
Registration Number
CTRI/2019/04/018460
Lead Sponsor
JIPMER
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All appropriate for gestational age exclusively breast fed apparently healthy term infants at 90-120days of age with hemoglobin >10.5gm/dl and MCV of 78fl.

Exclusion Criteria

Infants with congenital anomalies or genetic syndromes. Infants on iron supplementation already

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To determine whether initiation of supplemental iron at 90-120 days of age in apparently healthy exclusively breast term appropriate for gestational age infants prevent the development of IDA at 6months of age.Timepoint: To determine whether initiation of supplemental iron at 90-120 days of age in apparently healthy exclusively breast term appropriate for gestational age infants prevent the development of IDA at 6months of age.
Secondary Outcome Measures
NameTimeMethod
. To determine the efficacy of iron supplementation in preventing the development of iron depletion at 6months of age. <br/ ><br>2.To determine the efficacy of iron supplementation in preventing the development of iron deficient erythropoiesis at 6months of age. <br/ ><br>3.To evaluate the change in hemoglobin, ferritin and transferrin saturation levels between the age 90 to 120 days and 6 months.Timepoint: 6 months of age
© Copyright 2025. All Rights Reserved by MedPath